BioCentury | Apr 6, 2017
Company News

Ogeda, Astellas deal

...symptoms in breast and prostate cancer patients treated with hormone deprivation. Ogeda was known as Euroscreen S.A....
BioCentury | Apr 3, 2017
Company News

Ogeda takeout gives Astellas hot flashes candidate

...symptoms in breast and prostate cancer patients treated with hormone deprivation. Ogeda was known as Euroscreen S.A....
BioCentury | Oct 24, 2016
Financial News

Ogeda financial update

...Ogeda S.A. , Brussels, Belgium Business: Genitourinary, Endocrine/Metabolic, Neurology Date announced: 2016-10-19 Note: Ogeda (formerly Euroscreen S.A....
BioCentury | Sep 19, 2016
Clinical News

ESN364: Completed Phase IIa enrollment

...a double-blind, placebo-controlled, Belgian Phase IIa trial evaluating 90 mg oral ESN364 for 12 weeks. Euroscreen S.A....
BioCentury | Oct 12, 2015
Financial News

Euroscreen completes venture financing

Euroscreen S.A. , Brussels, Belgium Business: Proteomics Date completed: 2015-10-02 Type: Venture financing Raised: EUR16 million ($18 million) Investors: SFPI-FPIM; Fund+; Vesalius Biocapital Partners; Societe Regionale d’Investissement de Wallonie S.A.; BNP Paribas; Capricorn Venture Partners WIR...
BioCentury | Oct 8, 2015
Financial News

Euroscreen raises EUR 16M in series B

...as did existing investors Vesalius Biocapital II Partners; SRIW; and BNP Paribas Fortis Private Equity. Euroscreen...
BioCentury | Jan 17, 2011
Company News

Euroscreen, J&J deal

...commercialization. Euroscreen will receive an upfront payment and research funding over the next three years. Euroscreen...
...will have all rights to IP developed under the deal. Further terms were not disclosed. Euroscreen S.A....
BioCentury | Aug 12, 2010
Distillery Therapeutics

Indication: Cancer

...to isolate compounds that modulate biological activity of P2Y11 receptor patented; available for licensing from Euroscreen S.A....
BioCentury | Mar 17, 2008
Company News

Euroscreen, Progenics antibodies news

...Euroscreen said the European Patent Office rejected an opposition filed by Progenics to Euroscreen's European Patent...
...140 , a mAb against CCR5 that is in Phase II testing to treat HIV. Euroscreen's...
...CCR5 sequences, vectors, cell lines and screening methods to identify compounds that modulate CCR5 activity. Euroscreen S.A....
BioCentury | Sep 10, 2007
Company News

Euroscreen, Human Genome Sciences, Icos, Boehringer Ingelheim deal

...for any indication. Euroscreen is the licensing agent for the portfolio, which includes patents from Euroscreen...
..."the primary application of interest to companies at this time." Financial terms were not disclosed. Euroscreen S.A....
Items per page:
1 - 10 of 47
BioCentury | Apr 6, 2017
Company News

Ogeda, Astellas deal

...symptoms in breast and prostate cancer patients treated with hormone deprivation. Ogeda was known as Euroscreen S.A....
BioCentury | Apr 3, 2017
Company News

Ogeda takeout gives Astellas hot flashes candidate

...symptoms in breast and prostate cancer patients treated with hormone deprivation. Ogeda was known as Euroscreen S.A....
BioCentury | Oct 24, 2016
Financial News

Ogeda financial update

...Ogeda S.A. , Brussels, Belgium Business: Genitourinary, Endocrine/Metabolic, Neurology Date announced: 2016-10-19 Note: Ogeda (formerly Euroscreen S.A....
BioCentury | Sep 19, 2016
Clinical News

ESN364: Completed Phase IIa enrollment

...a double-blind, placebo-controlled, Belgian Phase IIa trial evaluating 90 mg oral ESN364 for 12 weeks. Euroscreen S.A....
BioCentury | Oct 12, 2015
Financial News

Euroscreen completes venture financing

Euroscreen S.A. , Brussels, Belgium Business: Proteomics Date completed: 2015-10-02 Type: Venture financing Raised: EUR16 million ($18 million) Investors: SFPI-FPIM; Fund+; Vesalius Biocapital Partners; Societe Regionale d’Investissement de Wallonie S.A.; BNP Paribas; Capricorn Venture Partners WIR...
BioCentury | Oct 8, 2015
Financial News

Euroscreen raises EUR 16M in series B

...as did existing investors Vesalius Biocapital II Partners; SRIW; and BNP Paribas Fortis Private Equity. Euroscreen...
BioCentury | Jan 17, 2011
Company News

Euroscreen, J&J deal

...commercialization. Euroscreen will receive an upfront payment and research funding over the next three years. Euroscreen...
...will have all rights to IP developed under the deal. Further terms were not disclosed. Euroscreen S.A....
BioCentury | Aug 12, 2010
Distillery Therapeutics

Indication: Cancer

...to isolate compounds that modulate biological activity of P2Y11 receptor patented; available for licensing from Euroscreen S.A....
BioCentury | Mar 17, 2008
Company News

Euroscreen, Progenics antibodies news

...Euroscreen said the European Patent Office rejected an opposition filed by Progenics to Euroscreen's European Patent...
...140 , a mAb against CCR5 that is in Phase II testing to treat HIV. Euroscreen's...
...CCR5 sequences, vectors, cell lines and screening methods to identify compounds that modulate CCR5 activity. Euroscreen S.A....
BioCentury | Sep 10, 2007
Company News

Euroscreen, Human Genome Sciences, Icos, Boehringer Ingelheim deal

...for any indication. Euroscreen is the licensing agent for the portfolio, which includes patents from Euroscreen...
..."the primary application of interest to companies at this time." Financial terms were not disclosed. Euroscreen S.A....
Items per page:
1 - 10 of 47